DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report
DBV Technologies (Euronext: DBV, Nasdaq: DBVT), a clinical-stage biopharmaceutical company focused on food allergies and immunologic conditions, has announced the filing of its 2024 Half-Year Report for the semester ended June 30, 2024. The report has been filed with the French market authority, Autorité des Marchés Financiers (AMF).
The 2024 Half-Year Report is now available for consultation or download in French on the company's website (www.dbv-technologies.com) under the Investors/Financial Information section, as well as on the AMF website (www.amf-france.org). Interested parties can also request a free copy by mail or email from DBV Technologies.
DBV Technologies (Euronext: DBV, Nasdaq: DBVT), un'azienda biofarmaceutica in fase clinica specializzata in allergie alimentari e condizioni immunologiche, ha annunciato la presentazione del suo Rapporto Semestrale 2024 per il semestre terminato il 30 giugno 2024. Il rapporto è stato depositato presso l'autorità di mercato francese, Autorité des Marchés Financiers (AMF).
Il Rapporto Semestrale 2024 è ora disponibile per la consultazione o il download in francese sul sito web dell'azienda (www.dbv-technologies.com) nella sezione Investitori/Informazioni Finanziarie, così come sul sito dell'AMF (www.amf-france.org). Le parti interessate possono anche richiedere una copia gratuita via posta o email a DBV Technologies.
DBV Technologies (Euronext: DBV, Nasdaq: DBVT), una empresa biofarmacéutica en etapa clínica centrada en alergias alimentarias y condiciones inmunológicas, ha anunciado la presentación de su Informe Semestral 2024 para el semestre finalizado el 30 de junio de 2024. El informe ha sido presentado ante la autoridad de mercado francesa, Autorité des Marchés Financiers (AMF).
El Informe Semestral 2024 ya está disponible para consulta o descarga en francés en el sitio web de la empresa (www.dbv-technologies.com) en la sección de Inversores/Información Financiera, así como en el sitio web de la AMF (www.amf-france.org). Las partes interesadas también pueden solicitar una copia gratuita por correo postal o electrónico a DBV Technologies.
DBV Technologies(Euronext: DBV, Nasdaq: DBVT)는 식품 알레르기 및 면역학적 질환에 중점을 둔 임상 단계의 생물 의약품 회사로, 2024년 6월 30일에 종료된 반기 보고서를 제출했다고 발표했습니다. 이 보고서는 프랑스 시장 당국인 Autorité des Marchés Financiers (AMF)에 제출되었습니다.
2024년 반기 보고서는 회사 웹사이트(www.dbv-technologies.com) 투자자/재무 정보 섹션에서 프랑스어로 상담하거나 다운로드할 수 있으며, AMF 웹사이트(www.amf-france.org)에서도 이용할 수 있습니다. 관심 있는 사람은 DBV Technologies에 우편이나 이메일로 무료 사본 요청도 가능합니다.
DBV Technologies (Euronext: DBV, Nasdaq: DBVT), une entreprise biopharmaceutique en phase clinique spécialisée dans les allergies alimentaires et les conditions immunologiques, a annoncé le dépôt de son Rapport Semestriel 2024 pour le semestre clos le 30 juin 2024. Le rapport a été déposé auprès de l'autorité de marché française, Autorité des Marchés Financiers (AMF).
Le Rapport Semestriel 2024 est désormais disponible pour consultation ou téléchargement en français sur le site web de l'entreprise (www.dbv-technologies.com) dans la section Investisseurs/Informations Financières, ainsi que sur le site de l'AMF (www.amf-france.org). Les parties intéressées peuvent également demander une copie gratuite par courrier ou par e-mail à DBV Technologies.
DBV Technologies (Euronext: DBV, Nasdaq: DBVT), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf Lebensmittelallergien und immunologische Erkrankungen konzentriert, hat die Einreichung seines Halbjahresberichts 2024 für das am 30. Juni 2024 beendete Halbjahr bekannt gegeben. Der Bericht wurde bei der französischen Marktaufsichtsbehörde, Autorité des Marchés Financiers (AMF), eingereicht.
Der Halbjahresbericht 2024 ist jetzt in französischer Sprache auf der Website des Unternehmens (www.dbv-technologies.com) im Bereich Investoren/Finanzinformationen zur Einsichtnahme oder zum Download verfügbar, ebenso wie auf der AMF-Website (www.amf-france.org). Interessierte Parteien können auch eine kostenlose Kopie per Post oder E-Mail von DBV Technologies anfordern.
- None.
- None.
Châtillon, France, July 30, 2024
DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the semester ended June 30, 2024, of its Half-Year Report with the French market authority, “Autorité des Marchés Financiers” (“AMF”).
The 2024 Half-Year Report can be consulted or downloaded from the Company’s website (www.dbv-technologies.com) in the section Investors/Financial Information, and on the AMF website (www.amf-france.org), in French only.
It is also available free of charge upon request:
- by mail : DBV Technologies – 107 avenue de la République 92320 Châtillon, France ;
- by email: investors@dbv-technologies.com.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary technology platform, Viaskin™, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one ordinary share) are traded on the Nasdaq Stock Market (Ticker: DBVT).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
Viaskin and EPIT are trademarks of DBV Technologies.
Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com
Media Contact
Angela Marcucci
DBV Technologies
angela.marcucci@dbv-technologies.com
Attachment
FAQ
When did DBV Technologies file its 2024 Half-Year Report?
Where can investors access DBV Technologies' (DBVT) 2024 Half-Year Report?
In which language is DBV Technologies' (DBVT) 2024 Half-Year Report available?
How can shareholders request a copy of DBV Technologies' (DBVT) 2024 Half-Year Report?
